Product Launch Details
Glenmark Therapeutics Inc., USA (Glenmark) announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump pack formats. The product is an over-the-counter acne treatment gel that contains the same active ingredient (Adapalene 0.1%) as Differin® Gel, 0.1%.
Market Context and Size
The target market for comparable products, specifically Differin® Gel, 0.1% (OTC) and all available therapeutic equivalents, achieved annual sales of approximately $45.8 million according to Nielsen® syndicated data for the 52-week period ending September 5, 2026.
Product Availability and Distribution
The newly launched pump packs are available in two sizes:
- 15g pump size available on Amazon and Walmart.com
- 45g pump size available on Amazon and Walmart.com
Management Commentary
Marc Kikuchi, President & Business Head, North America, stated: "The introduction of Adapalene Gel USP, 0.1% (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio. This launch reflects our commitment to delivering high-quality and affordable healthcare solutions that meet evolving consumer needs."
Regulatory and Legal Disclaimers
The product is only marketed for the indications listed in Glenmark's approved drug facts label. Glenmark clarifies that their product is not manufactured or distributed by Galderma Laboratories, L.P. and/or Galderma Holding S.A., who distribute DIFFERIN® Gel and own the registered trademark DIFFERIN® respectively.
Company Background
Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company with 11 world-class manufacturing facilities across four continents, supported by six R&D centres, and commercial footprint in 80+ countries. The company focuses on respiratory, dermatology, and oncology therapeutic areas and is positioned among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024 (Scrip 100).